Gender-specific determinants of blood pressure (BP) values and control have not been the focus of clinical hypertension research. The purpose of this analysis was to identify gender-specific and multi-level (physician and patient) determinants of BP values and predictors of uncontrolled BP. We completed a subgroup analysis comparing men and women who participated in the Belgian PREVIEW study of second-line treatment effectiveness of valsartan, applying two-level hierarchical modelling of 90-day BP values and guideline-defined BP control. In total, 1665 women and 1525 men were treated by 504 general practitioners. Fewer women than men reached systolic BP (SBP) (P ¼ 0.015) and combined BP targets at 90 days (P ¼ 0.007). More than 26% of the variance in 90-day SBP (intra-class correlation coefficient (ICC) ¼ 0.270) and diastolic BP (DBP) (ICC ¼ 0.262) was attributable to physicianlevel factors for men; the physician-level ICCs for SBP and DBP were 0.259 and 0.268, respectively, for women. Determinants of 90-day BP values and predictors of uncontrolled BP varied considerably by gender. Many of the multi-level determinants of BP by gender are amenable to intervention, and the remainder can serve as warning signs to clinicians that patients may remain vulnerable to poor outcomes associated with sub-optimal BP control.
Introduction
Arterial hypertension affects approximately one billion individuals worldwide 1 and is a leading cause of death in industrialized countries. 2 Patients with poorly controlled blood pressure (BP) are at high risk for target end-organ damage and cardiovascular morbidity and mortality. [3] [4] [5] [6] Achieving guideline-recommended BP targets, [7] [8] [9] [10] however, is difficult in the majority of patients with chronic hypertension. [11] [12] [13] [14] [15] [16] Determinants of poor BP control are multi-level. That is, previously identified factors that contribute to poor BP control have included physician-related factors, such as physician age, 17 willingness to accept high BP values 18 and so-called 'therapeutic inertia, ' 19 as well as patient-related factors, including age, 20, 21 treatment adherence 22, 23 and gender. [24] [25] [26] An area of clinical interest that has not received attention is whether or not the multi-level determinants of BP control are gender-specific. With significant gender differences in underlying hypertension prevalence, 1 awareness, 21 progression 27, 28 and levels of control, 14, 24, 25 it seems plausible that determinants of BP control also could differ between women and men. Accordingly, we report here on the subgroup analyses for, respectively, 1665 female and 1525 male patients who participated in the PRE-VIEW study in Belgium. 29 This prospective, multicenter, pharmacoepidemiological study examined multi-level determinants and predictors of BP reduction and control after second-line treatment with the angiotensin II receptor blocker valsartan over a period of 90 days. A total of 3194 patients in whom first-line antihypertensive treatment failed or was not tolerated were recruited into the study by 504 general practitioners (GP).
The purpose of this subgroup analysis was fourfold: (1) to describe potential gender differences in socio-demographics, cardiovascular history or risk, antihypertensive treatment, as well as BP values and control at 90 days; (2) to quantify the proportions of variance in BP values at 90 days attributable to physician-level versus patient-level factors for men and women; (3) to identify the multilevel (physician and patient) determinants of BP values at 90 days by gender; and (4) to identify independent and gender-specific predictors of uncontrolled BP at 90 days.
Methods
The methodology of the PREVIEW study is described in detail in the primary paper. 29 Key elements are summarized below. Not repeated here but available in the original paper are: inclusion and exclusion criteria; recruitment, screening and enrolment procedures; sample size calculations; schedule of assessment; details on variables and measurement; procedures for data collection, management and analysis; and descriptive and comparative statistical analysis. Also described in Van der Niepen et al. 29 are data related to physician knowledge of, and practise in accordance with evidence-based best practise guidelines (BPGs) for hypertension management. Patient classification as to their vulnerability to uncontrolled BP derived from a cluster analysis (vulnerable vs highly vulnerable patient clusters) and also has been described elsewhere. 30 A key objective of the PREVIEW study was to examine both patient-and physician-level determinants of variability in BP values and control at 90 days.
Samples for subgroup analyses
Like the patients in the sample at large, selfidentified female and male subsamples consisted of patients whose treating physicians had decided independently, per best clinical judgment, and within the approved label and reimbursement regulations to prescribe one of three treatment formulations of valsartan (80, 160 and 80 mg per 12.5 mg hydrochlorothiazide) as second-line monoor combination therapy because first-line antihypertensive therapy failed or was not tolerated. Patients with known sensitivity to angiotensin II receptor blockers or hydrochlorothiazide were excluded, as were patients concomitantly treated with an angiotensin II receptor blocker other than valsartan. This investigation conforms to the principles outlined in the Declaration of Helsinki. All patients provided written informed consent. Human subject approval was granted by the medical ethical committee, Universitair Ziekenhuis, Vrije Universiteit Brussel (Belgium).
Measurement
Physician-level data. Physician-level data were collected through self-report using an investigatordeveloped questionnaire. Physician demographics and practise type, location, setting, and patient mix as well as sources of information (BPGs) and knowledge related to hypertension were assessed. In addition, data on hypertension management practises, prescription patterns, management of side effects, and perceptions of systolic BP (SBP) and diastolic BP (DBP) thresholds for treatment initiation and intensification, and patient adherence also were assessed.
Patient-level data. The study included only patient data collected routinely in clinical practise; no additional tests or exams were ordered. Patient demographics, hypertension and cardiovascular history, comorbidities, lifestyle, previous antihypertensive medications, clinical status, starting valsartan dose, class of concomitant antihypertensive medications and self-reported adherence within the past 4 weeks were assessed at baseline. BP was measured three times at 1-to 2-min intervals, in a sitting position after 5-min of rest, using a calibrated standard sphygmomanometer and appropriately sized cuff placed at heart level. The mean of all three sitting measurements without rounding was recorded as the mean sitting SBP (MSSBP) and the mean sitting DBP (MSDBP). Follow-up data (90 days after baseline) included both MSSBP and MSDBP, as well as concomitant medication(s) taken or changed since previous visit, changes in valsartan dose since previous visit, cholesterol levels, side effects and self-reported adherence with valsartan therapy within the past 4 weeks.
Statistical analysis
Standard descriptive statistics were used to describe the gender subsamples, including proportions and appropriate measures of central tendency and dispersion. Comparative analyses between men and women were completed using independent sample t-tests without assuming equal variance and Pearson's or Yates' w 2 -tests (contingency corrected) where appropriate. We hypothesized that MSSBP and MSDBP outcomes in each subsample were related to physician-and patient-level variables. Each participating physician recruited several patients, therefore patients could not be considered independent but instead 'nested' under their treating physician. Thus, we assumed that the n j patients recruited by the jth physician might share some proportion of variance in BP values attributable to their common physician; and that this physician influence might influence BP values before any patient-specific variables. We applied a two-level hierarchical linear modelling method for each subsample. 31 The intra-class correlation coefficient (ICC) quantified the variability in patient outcome attributable to within-physician variability before any patient-level determinants were considered. Hierarchical logistic regression was used for each subsample to identify physician-and patient-level variables associated with not meeting JNC-7/ESH-ESC guidelines-defined BP control (140/90 mm Hg; 130/80 mm Hg for diabetics). 7, 8 Data were analyzed using SPSS v15 (SPSS, Chicago, IL, USA). Statistical significance was predetermined as a P-value o0.05. Corrections for multiplicity were applied as necessary.
Results
Physician characteristics (n ¼ 504) In brief, the majority of the physician sample was male (88. 1%), certified (82.1%) and practising solo (78.2%) to a mixed population of all ages (81.7%) (data not shown). 29 Mean age was 47.4±8.1 years and the average years of clinical practise was 20.7±8.9 years. The median number of hypertensive patients observed in the 12 months before baseline was 100 (mean 226.1 ± 279.4). On average, physicians spent 19.4 ± 5.8 min in their first visit with a newly diagnosed hypertensive patient and saw new hypertensive patients 4.4 ± 6.3 times in the first 3 months after diagnosis.
Gender differences in patient characteristics
Of the 3190 patients with evaluable data, 1665 (52.2%) were women whereas 1525 (47.8%) were men. Women (aged 23-97) were on average 3.66 years older than men (aged 27-91) ( Table 1) . A significantly smaller proportion of women than Renal impairment defined as serum creatinine 41.5 mg per 100 ml. Missing data not reported, thus totals may not equal 100%.
Gender and blood pressure outcomes K MacDonald et al men had a history of myocardial infarction, coronary revascularization, haemorrhagic cerebrovascular accidents, intermittent claudication, and peripheral vascular bypass or stent procedures. Conversely, a larger proportion of women than men had a history of transient ischaemia attacks and microalbuminuria. Fewer women than men smoked or reported excessive alcohol intake; more women than men lacked regular exercise and were obese. Women also had higher levels of total cholesterol and high-density lipoprotein than men at baseline.
Gender differences in hypertension history and treatment On average, women had been treated for hypertension longer than men (6.07±6.57 vs 4.99±5.53 years; t ¼ 5.064; Po0.001), and at baseline had previously received more of the six antihypertensive classes as first-line treatment than men (1.72±0.87 vs 1.65 ± 0.89 classes; t ¼ 2.435; P ¼ 0.015). There were no gender differences comparing the duration of first and subsequent GP visits for the management of hypertension. There were no differences in treatment with valsartan by gender ( Table 1) . A greater proportion of women than men, however, were treated with concomitant diuretics, and a significantly smaller proportion of women than men were treated with concomitant calcium channel blockers and concomitant a-adrenergic blockers.
Gender differences in BP and control Women had higher values of MSSBP than men at baseline (t ¼ 2.432; P ¼ 0.015) ( Gender-specific determinants of 90-day BP 90-day SBP. In total, 27% of the variance in 90-day MSSBP was attributable to physician-level factors for men (ICC ¼ 0.270); 25.9% of the variance in 90-day MSSBP was attributable to physician-level factors for women (ICC ¼ 0.259). Treating physician years of practise experience were associated with higher MSSBP values for both men and women ( Table 3 ). The number of hypertensive patients observed by the treating physician in the last 12 months and more BPG-concordant practises were associated with lower MSSBP values for both men and women. Longer duration of physician visits for antihypertensive medication titration was associated with higher MSSBP values, but only for women.
In all, 73% of the variance in 90-day MSSBP was attributable to patient-level factors for men (ICC ¼ 0.730); 74.1% of the variance in 90-day MSSBP was attributable to patient-level factors for women (ICC ¼ 0.741). Older patient age and being classified as a highly vulnerable patient were number of visits during the first 3 months to achieve BP control and more BPG-concordant practises were associated with lower MSDBP values for both men and women (Table 4 ). The number of hypertensive patients observed by the treating physician in the past 12 months was associated with lower MSDBP values for women only. In all, 73.8% of the variance in 90-day MSDBP was attributable to patient-level factors for men (ICC ¼ 0.738) and 73.2% of the variance in 90-day MSDBP was attributable to patient-level factors for women (ICC ¼ 0.732). Older patient age was associated with lower MSDBP values for both men and women (Table 4) . Being classified as a highly vulnerable patient and being prescribed a concomitant angiotensin-converting enzyme inhibitor both were associated with lower MSDBP values for men and women. Being a current smoker, obesity, valsartan dosing, and being prescribed concomitant diuretics and a-adrenergic blockers were factors in 90-day MSDBP values for men only. Conversely, being prescribed a concomitant calcium channel blocker, each incidence of not taking valsartan, and days since the most recent BP measurement were associated with higher MSDBP values for women only.
Gender-specific determinants of 90-day BP control Significant determinants of uncontrolled 90-day BP are presented in Table 5 . Having diabetes mellitus and being a highly vulnerable patient were Gender and blood pressure outcomes K MacDonald et al independently associated with greater odds of having uncontrolled SBP and DBP, isolated or combined, for both men and women. Older patient age was associated with a greater odds of uncontrolled SBP for women, and lower odds of uncontrolled DBP for men. Non-adherent days and concomitant angiotensin-converting enzyme inhibitors were associated with greater odds of uncontrolled SBP and DBP, respectively, for men only. More BPG-concordant practises were associated with lower odds of uncontrolled SBP for women, and lower odds of uncontrolled DBP, and combined SBP and DBP for men and women. The number of hypertensive patients observed in the past 12 months reduced the odds of uncontrolled SBP, DBP, and combined SBP and DBP for women only. Treating physician years of practise increased the odds of uncontrolled SBP for men, DBP for women, and combined SBP and DBP for men only. The mean number of visits in the first 3 months to achieve BP control was associated with lower odds of uncontrolled DBP, and the number of correct physician BP knowledge questions was associated with greater odds of uncontrolled DBP for women only. (Summaries and comparisons gender differences in BP values and BP control are presented in Tables 6 and 7 ).
Discussion
Our principal findings were that, in this sample of 1664 women and 1525 men with hypertension being treated in second-line with valsartan as part of the PREVIEW study, (1) women and men had different clinical profiles regarding cardiovascular history, lifestyle behaviours and risk factors, history of antihypertensive treatment, and concomitant antihypertensive therapy, (2) fewer women than men reached guideline-specified SBP (36.3 vs 41.2%) and combined SBP-DBP targets (32.4 vs 36.7%) after 90 days of treatment, (3) the proportion of variance in BP values attributed to physician-and patientlevel factors were different comparing men and women, and (4) the determinants of BP values and likelihood of BP control varied considerably by gender. Importantly, these data are compelling evidence that many of the gender-specific determinants of BP values and likelihood of BP control are modifiable, or can serve as strong warning signs of patient at a greater risk of poor outcomes associated with sub-optimal BP control.
Modifiable determinants of BP and BP control. For men in this sample, the modifiable lifestyle behaviours of smoking and lack of regular exercise were determinants of higher levels of SBP, smoking and obesity were determinants of higher levels of DBP, and male patients who lacked regular exercise were 9 to 85% more likely to have uncontrolled SBP than male patients who exercised regularly. Three aspects of these results are intriguing. First, twice as many men than women smoked. Thus, a large proportion of the male population (38.4%) is at risk for higher Gender and blood pressure outcomes K MacDonald et al BP because of this modifiable behaviour alone. Second, while more women than men reported lacking regular exercise, this factor had an SBP-raising effect for men only, and increased the likelihood that male patients only would have uncontrolled SBP. Third, more women than men were obese in this sample; yet, obesity had a DBPraising effect for men only. Taken together, these data also indicate that antihypertensive treatment is less effective in men who smoke, lack regular exercise and/or men who are obese. In contrast, certain modifiable behaviours had a BP-raising effect for women in the sample. Namely, each time that valsartan was not taken as prescribed in the 4 weeks preceding measurement came with a 0.4 mm Hg increase in SBP and a 0.3 mm Hg increase in DBP for women, whereas each non-adherent day in the 4 weeks preceding measurement came with a 1-13% increase in the likelihood of uncontrolled SBP for men only. This may be due, at least in part, because fewer women than men reached guideline-specified SBP targets. Days since last BP measurement before enrolment also had a significant but small SBP and DBP-raising effect for women only. This behaviour too is modifiable by encouraging female hypertensive patients in particular to have their BP measured more frequently or alternatively measure BP at home.
There were also several modifiable physicianlevel factors associated with BP values and levels of control. Similar to the findings of Choudhry et al., 32 physician years of clinical practise had a BP-raising effect for both men and women, and increased the odds of uncontrolled BP. Moreover, BPG-concordant practises were associated with improved BP control. Although years of physician practise is not a feasible target for intervention, improving efforts to increase the guideline-concordant practise and overcoming 'therapeutic inertia' 19 may be vital to improving intermediary and clinical outcomes in the hypertensive population.
Warning signs of poor BP control
Although women in this sample had received more classes of antihypertensive medications before the Abbreviations: ACE, angiotensin-converting enzyme; BPG, best practise guideline; CI, confidence interval; DBP, diastolic blood pressure; GP, general practitioner; OR, adjusted odds ratio; SBP, systolic blood pressure.
Gender and blood pressure outcomes K MacDonald et al addition of valsartan than men, they also were treated for hypertension longer on average. Moreover, there was considerable variation in concomitant medications comparing men and women. Of particular note, however, BP control of women in this sample was more sensitive to physician guideline concordant practises and experience in treating more cases of hypertension than men. This may reflect gender differences in hypertension complexity, or be indicative of aspects of the care of female hypertensive patients that are not being addressed effectively in clinical practise. Our finding that diabetes mellitus is a complicating comorbidity for men and women with hypertension is in concert with the primary study conclusions, 29 and is a common clinical concern. 33, 34 Mean BP level was comparable for diabetic and non-diabetic patients; however, because of the lower BP targets, lower BP control rates are observed in the diabetic subgroup. What our findings contribute to the growing body of knowledge regarding the complex relationship between diabetes and hypertension, however, is that women with diabetes are more likely to have uncontrolled BP than men with diabetes, compared with women and men without diabetes, respectively. That is, women with diabetes are approximately 45% more likely to have uncontrolled SBP 35 but the disparity in reaching BP control is even more pronounced when comparing men and women with diabetes mellitus. Accordingly, women in general and women with diabetes mellitus in particular may require more vigilant evaluation, greater treatment intensity and arguably treatment under physicians who treat greater numbers of hypertensive patients and who practise in concordance with BPGs to achieve BP control.
Interestingly, certain factors that were prominent in the full primary study population 29 (men and women) were not independent predictors of BP control for either gender. That is, GP practises consistent with BPGs regarding SBP and DBP triggers for treatment intensification were not independent predictors of uncontrolled SBP or DBP, respectively, for men or women. Instead, the total of all BPG-concordant practises was an important predictor of uncontrolled SBP for women and uncontrolled DBP for both men and women. As another example, the number of non-adherent days was a predictor of uncontrolled SBP and DBP for the entire PREVIEW sample, but not for men or women when stratified separately. Thus, although it is important to consider all hypertensive patients collectively, understanding gender-specific determinants of BP outcomes is helpful in planning more individualized patient care.
Limitations and future research
This was a secondary analysis of observational study data collected in a naturalistic setting, presumably with more heterogeneity in both physician practises and patient characteristics compared with experimental studies. Moreover, the parent study was not designed specifically to evaluate gender differences in antihypertensive treatment outcomes. Accordingly, future and potentially prospective studies may be needed to further validate our principal findings. Physician gender was not a significant factor in our hierarchical modelling of BP outcomes; but, almost 90% of participating physicians were male. Considering that women and men may approach patient care differently and in recognition of the trend toward a more balanced gender distribution among 
Conclusion
Several common significant determinants and predictors of BP values and BP control were identified for men and women. For example, patient age, highly vulnerable cluster membership, and concomitant angiotensin-converting enzyme inhibitor, years of GP practise experience and the total number of BPG-concordant practises influenced BP values for both men and women. Further, diabetes mellitus, highly vulnerable cluster membership and the total number of BPG-concordant practises had an influence on BP control for men and women. Alternatively, several gender-specific determinants of BP values and BP control were identified, including several physician-level and several patient-level factors. For instance, beyond the influence of diabetes mellitus and high vulnerability cluster membership, men who lacked regular exercise or were non-adherent were more vulnerable to uncontrolled SBP, whereas women were more vulnerable to uncontrolled BP because of identifiable physician-level factors including the number of hypertensive patients observed in the past 12 months, and the number of follow-up visits to achieve BP control. Understanding these differences is helpful in identifying multi-level gender-specific determinants of BP that are amenable to intervention or can serve as warning signs to clinicians that patients may remain vulnerable to poor outcomes associated with sub-optimal BP control. What is known about topic K Hypertension awareness and progression are different in men than in women. K Rates of blood pressure control are lower in men than in women with hypertension.
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